midostaurin   Click here for help

GtoPdb Ligand ID: 5702

Synonyms: CGP 41231 | CGP 41251 | N-benzoylstaurosporine | PKC412 | Rydapt®
Approved drug PDB Ligand Immunopharmacology Ligand
midostaurin is an approved drug (FDA & EMA (2017))
Compound class: Synthetic organic
Comment: Midostaurin is an analogue of staurosporine, and was originally described as a PKC inhibitor [5]. It was later reported as an inhibitor of fms-related tyrosine kinase 3 (FLT3) [6].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 1
Rotatable bonds 4
Topological polar surface area 77.73
Molecular weight 570.23
XLogP 7.8
No. Lipinski's rules broken 1
Click here for help
Canonical SMILES COC1C(CC2OC1(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3CNC1=O)N(C(=O)c1ccccc1)C
Isomeric SMILES CO[C@@H]1[C@@H](C[C@H]2O[C@]1(C)n1c3ccccc3c3c1c1n2c2ccccc2c1c1c3CNC1=O)N(C(=O)c1ccccc1)C
InChI InChI=1S/C35H30N4O4/c1-35-32(42-3)25(37(2)34(41)19-11-5-4-6-12-19)17-26(43-35)38-23-15-9-7-13-20(23)28-29-22(18-36-33(29)40)27-21-14-8-10-16-24(21)39(35)31(27)30(28)38/h4-16,25-26,32H,17-18H2,1-3H3,(H,36,40)/t25-,26-,32-,35+/m1/s1
Immunopharmacology Comments
Midostaurin is a clinically used fms-related tyrosine kinase 3 (FLT3) inhibitor.
Immunopharmacology Disease
Disease X-Refs Comment References
Acute myeloid leukemia Disease Ontology: DOID:9119
OMIM: 601626
Orphanet: ORPHA519
Approved drug for FLT3 mutation +ve AML.
Mastocytosis Disease Ontology: DOID:350
FDA approved drug for aggressive systemic mastocytosis and systemic mastocytosis with associated hematological neoplasm or mast cell leukemia. EMA orphan drug for mastocytosis.